Shots:

• The US FDA has accepted IND to assess the safety- tolerability- PK- and preliminary antitumor activity of XB002 in patients with advanced solid tumors. The P-I trial is expected to initiate in Q2’21
• The preclinical data demonstrated that XB002 binds to tissue factors without affecting the coagulation cascade- in contrast with prior therapies in this class. The data also showed improved tolerability- tumor growth inhibition and complete regression
• XB002 (ICON-2) is an ADC composed of a human mAb against tissue factor and have an improved therapeutic index and favorable safety profile compared with earlier-generation tissue factor-targeting ADCs

  Ref: Exelixis | Image: Exelixis